Regeneron (REGN): Revisiting Valuation After Japan’s Dupixent Pediatric Asthma Approval and Bullish Investor Positioning

Simply Wall St.2025-12-25

Regeneron Pharmaceuticals (REGN) just picked up an important regulatory win in Japan, where Dupixent was cleared to treat severe pediatric asthma, and the stock is reacting as investors reassess its ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2594253367?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/company-cover/33715-main-header/1756202993919","is_english":true,"pubTime":"2025-12-25 23:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2594253367","market":"hk","top_or_hot":-1,"title":"Regeneron (REGN): Revisiting Valuation After Japan’s Dupixent Pediatric Asthma Approval and Bullish Investor Positioning","media":"Simply Wall St.","content":"<div>\n<p>Regeneron Pharmaceuticals (REGN) just picked up an important regulatory win in Japan, where Dupixent was cleared to treat severe pediatric asthma, and the stock is reacting as investors reassess its ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-regn/regeneron-pharmaceuticals/news/regeneron-regn-revisiting-valuation-after-japans-dupixent-pe\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Regeneron (REGN): Revisiting Valuation After Japan’s Dupixent Pediatric Asthma Approval and Bullish Investor Positioning</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRegeneron (REGN): Revisiting Valuation After Japan’s Dupixent Pediatric Asthma Approval and Bullish Investor Positioning\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-12-25 23:21 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-regn/regeneron-pharmaceuticals/news/regeneron-regn-revisiting-valuation-after-japans-dupixent-pe><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Regeneron Pharmaceuticals (REGN) just picked up an important regulatory win in Japan, where Dupixent was cleared to treat severe pediatric asthma, and the stock is reacting as investors reassess its ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-regn/regeneron-pharmaceuticals/news/regeneron-regn-revisiting-valuation-after-japans-dupixent-pe\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4112","symbol_name":"金融交易所和数据","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-regn/regeneron-pharmaceuticals/news/regeneron-regn-revisiting-valuation-after-japans-dupixent-pe","article_id":"2594253367","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/company-cover/33715-main-header/1756202993919"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-regn/regeneron-pharmaceuticals/news/regeneron-regn-revisiting-valuation-after-japans-dupixent-pe","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2594253367","pubTimestamp":1766676106,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Regeneron Pharmaceuticals (REGN) just picked up an important regulatory win in Japan, where Dupixent was cleared to treat severe pediatric asthma, and the stock is reacting as investors reassess its long term growth story.\nSee our latest analysis for Regeneron Pharmaceuticals.\nThat backdrop of new Dupixent approvals comes after a powerful run, with roughly a 41 percent 90 day share price return and a solid 5 year total shareholder return of about 65 percent, suggesting momentum is still very...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4112":"金融交易所和数据","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","LU1974910355.USD":"Allianz Thematica Cl AMg DIS USD","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","LU0823434583.USD":"BNP PARIBAS US GROWTH \"C\" (USD) ACC","LU2237438978.USD":"Amundi Funds US Pioneer A2 (C) USD","LU0823434740.USD":"BNP PARIBAS US GROWTH \"C\" (USD) INC","LU0058720904.USD":"联博国际健康护理基金A","LU0053666078.USD":"摩根大通基金-美国股票A（离岸）美元","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","LU2362541273.HKD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (HKD) ACC","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU2362541513.USD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (USD) ACC","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","BK4585":"ETF&股票定投概念","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU2023250504.SGD":"Allianz Thematica Cl AMg DIS H2-SGD","LU1917777945.USD":"安联专题基金Cl AT Acc","BK4139":"生物科技","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","LU2362540622.SGD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (SGDHDG) ACC","REGN":"再生元制药公司","LU2106854487.HKD":"ALLIANZ THEMATICA \"AMG\" (HKD) INC","LU0882574055.USD":"富达全球健康医疗A ACC","BK4588":"碎股"},"translate_title":"再生元(REGN)：在日本Dupixent儿童哮喘批准和看涨投资者定位后重新审视估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"REGN":1.98},"content_text":"Regeneron Pharmaceuticals (REGN) just picked up an important regulatory win in Japan, where Dupixent was cleared to treat severe pediatric asthma, and the stock is reacting as investors reassess its long term growth story. See our latest analysis for Regeneron Pharmaceuticals. That backdrop of new Dupixent approvals comes after a powerful run, with roughly a 41 percent 90 day share price return and a solid 5 year total shareholder return of about 65 percent, suggesting momentum is still very much in Regeneron's favor. If this kind of steady execution appeals to you, it could be a good moment to scan other innovative drug makers through our curated healthcare stocks. With the shares hovering near analyst targets but still trading at a sizable intrinsic discount, the question now is simple: is Regeneron still mispriced, or are investors already baking in every ounce of its future growth? Most Popular Narrative Narrative: 0% Overvalued With Regeneron closing at $783.71 against a narrative fair value near $781, the story hinges less on a big gap and more on how durable its growth really is. Regeneron's broad and advancing pipeline including recent or upcoming pivotal data in immunology, oncology (notably Lynozyfic and odronextamab), genetic medicines, and obesity positions the company to benefit from demographic driven increases in demand for advanced therapies and from the rise in personalized and precision medicine, supporting future revenue growth and pipeline driven earnings upside. Read the complete narrative. Want to see what kind of steady revenue climb and margin path this narrative is baking in, and how rich a future earnings multiple it assumes? The underlying projections tell a very specific story about how much more profit Regeneron might squeeze from its pipeline strengths than the wider market expects. Curious which combination of growth, profitability, and discount rate assumptions has been used to land on that finely balanced fair value? Dive in to see how those moving parts add up. Result: Fair Value of $781 (ABOUT RIGHT) Have a read of the narrative in full and understand what's behind the forecasts. However, persistent Eylea competition and potential regulatory or manufacturing setbacks could quickly challenge those growth assumptions and pressure Regeneron’s carefully balanced valuation case. Find out about the key risks to this Regeneron Pharmaceuticals narrative. Another View: Valuation Through Earnings Step away from narrative fair value and REGN still looks inexpensive on plain earnings math. Its P E ratio sits around 17.6 times, versus 23.2 times for peers and 22.2 times for the wider US biotech group. Our fair ratio sits even higher at 27.6 times, which hints at upside if sentiment turns. See what the numbers say about this price — find out in our valuation breakdown. NasdaqGS:REGN PE Ratio as at Dec 2025 Build Your Own Regeneron Pharmaceuticals Narrative If you see the story differently or want to stress test the numbers yourself, you can build a custom view in just minutes: Do it your way. A good starting point is our analysis highlighting 3 key rewards investors are optimistic about regarding Regeneron Pharmaceuticals. Looking for more investment ideas? Before you move on, lock in a few fresh angles by scanning targeted stock ideas on Simply Wall Street that many investors overlook until it is too late.  Explore stocks with smaller share prices and financial strength by checking out these 3626 penny stocks with strong financials with fundamentals that support their growth stories. Review these 24 AI penny stocks that combine artificial intelligence with scalable business models. Consider these 10 dividend stocks with yields > 3% that may help support long-term compounding of income and value.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.The New Payments ETF Is Live on NASDAQ:Money is moving to real-time rails, and a newly listed ETF now gives investors direct exposure. Fast settlement. Institutional custody. Simple access.Explore how this launch could reshape portfoliosSponsored ContentNew: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2594253367","isCrawlerRequest":true}